| Identification | Back Directory | [Name]
tert-Butyl 2-bromo-4-fluorobenzoate | [CAS]
889858-12-2 | [Synonyms]
tert-Butyl 2-bromo-4-fluorobenzoate
tera-butyl 4-Bromo-2-fluorobenzoate
tert-Butyl 2-fluoro-4-bromobenzoate
2-Methylpropan-2-yl 4-bromo-2-fluorobenzoate
4-Bromo-2-fluoro-benzoic acid tert-butyl ester
Benzoic acid,4-bromo-2-fluoro-, 1,1-dimethylethyl ester | [Molecular Formula]
C11H12BrFO2 | [MDL Number]
MFCD08703426 | [MOL File]
889858-12-2.mol | [Molecular Weight]
275.11 |
| Chemical Properties | Back Directory | [Boiling point ]
305.7±27.0 °C(Predicted) | [density ]
1.394±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Oil | [color ]
Clear Colourless |
| Hazard Information | Back Directory | [Uses]
tert-Butyl 4-Bromo-2-fluorobenzoate is an intermediate of enzalutamide (M199800). Enzalutamide is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer. | [References]
[1] Patent: WO2016/102482, 2016, A1. Location in patent: Page/Page column 114
[2] Patent: US9242996, 2016, B2. Location in patent: Page/Page column 248; 251
[3] Patent: WO2016/97004, 2016, A1. Location in patent: Page/Page column 108 |
|
|